CSE Bulletin: Consolidation - Lobe Sciences Ltd.

CSE Bulletin: Consolidation - Lobe Sciences Ltd.

lobe sciences ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares.

As a result, the outstanding common shares of the Issuer will be reduced to approximately 38,230,000 common shares.

Further to the Issuer's news release dated June 6, 2022, the record date has been changed to June 10, 2022.

Trading will remain halted June 9, 2022 and resume on a consolidated basis June 10, 2022.

The name and symbol will not change.

Please note that all open orders will be cancelled at the close of business on June 9, 2022. Dealers are reminded to re-enter their orders taking into account the share consolidation.

_________________________________

lobe sciences ltd. (l'« émetteur ») a annoncé un regroupement de ses actions ordinaires émises et en circulation sur la base d'une (1) action ordinaire post-regroupement pour six (6) actions ordinaires pré-regroupement.

Par conséquent, les actions ordinaires en circulation de l'Émetteur seront réduites à environ 38 230 000 actions ordinaires.

Suite au communiqué de presse de l'Emetteur du 6 juin 2022, la date d'enregistrement a été reportée au 10 juin 2022.

Les échanges resteront interrompus le 9 juin 2022 et reprendront sur une base consolidée le 10 juin 2022.
Le nom et le symbole ne changeront pas.

Veuillez noter que tous les ordres ouverts seront annulés à la fermeture des bureaux le 9 juin 2022. Il est rappelé aux concessionnaires de saisir à nouveau leurs ordres en tenant compte du regroupement d'actions.

Trading on a Consolidated Basis/Négociation sur une base consolidée:

Le 10 juin/June 2022

Record Date/Date d'enregistrement:

Le 10 juin/June 2022

Symbol/Symbole:

LOBE

NEW/NOUVEAU CUSIP:

53946V 20 6

NEW/NOUVEAU ISIN:

CA53946V 20 6 6

Old/Vieux CUSIP & ISIN:

53946V107/CA53946V1076

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

GoldInxs Mining

GoldInxs Mining Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
GoldInxs Mining (TSXV:INXS)

GoldInxs Mining

Early-stage, discovery driven copper-gold projects in BC, Canada, with district-scale exploration upside located in the most prolific mining camps

Early-stage, discovery driven copper-gold projects in BC, Canada, with district-scale exploration upside located in the most prolific mining camps Keep Reading...
Stethoscope rests on stacks of US money over a bright blue background.

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the deal is BPL-003, a clinic-administered nasal spray derived from dimethyltryptamine... Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell's pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in Bria-Cell's ongoing pivotal Phase 3 study in metastatic breast cancer briacell... Keep Reading...
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solutionsBria-IMT is currently being evaluated in... Keep Reading...
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...
Rows of multicolored test tubes with brown, purple, blue and green caps arranged neatly on a white rack.

Merck KGaA to Acquire Bio-Techne in US$11.3 Billion Deal

Merck KGaA (ETR:MRK,OTCPL:MKGAF) has agreed to acquire life sciences supplier Bio-Techne (NASDAQ:TECH) for US$11.3 billion in cash, marking the firm’s largest transaction in a decade.Under a definitive agreement announced on Thursday (June 25), Merck KGaA will pay US$73 per share, representing a... Keep Reading...
GoldInxs Mining

GoldInxs Mining Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News